

**Applicant Inquiries & Answers for (RFA) #SUPP1002-
Mobile medication Units**

1. Is it necessary to be a methadone provider to apply?

Response: Yes. As noted on page 5 of the RFA, eligible bidders are voluntary agencies or other not-for-profit organizations that currently operate OASAS certified OTPs.

2. Are proposals expected to give methadone on the MMU vs. suboxone?

Response: Mobile Medication Units (MMUs) are permitted to administer or dispense OASAS-approved medication for the purpose of maintenance or detoxification treatment for substance use disorder, including Schedule II-V controlled substances. For this RFA, at a minimum, MMUs are expected to dispense methadone AND buprenorphine.

3. Can an agency bill for services provided as part of the MMU?

Response: Providers should bill for services provided on the Mobile Medication Unit as they would at a brick-and-mortar location.

4. Cover sheet and page 5 instructions say mail or hand deliver application to OASAS office in Albany... with no electronic or fax submissions accepted. Attachment B says email form to covidfunds@oasas.ny.gov email address. Can you direct me as to which one is correct??

Response: Applications must be submitted via mail or hand delivered to the OASAS office in Albany. The reference to email submissions has been removed from the Budget form on the OASAS website.

5. Do you have to serve the entire service area (would you have to serve all five boros of NYC)?

Response: OASAS expects Mobile Medication Units (MMUs) to provide services in areas of greatest need within an Economic Development Zone (EDZ) and reserves the right to determine these areas. Some EDZs will require servicing the entire service area due to the large need and logistical possibilities, while others require servicing only specific pockets of the EDZ. At a minimum, providers should take into consideration the following factors: the ability of the MMU to return to the Opioid Treatment Program (OTP) at the end of each operational day (unless the OTP intends on obtaining a separate waiver from the DEA that enables the MMU to waive this requirement), areas with gaps in OTP services, areas with a high patient (and potential patient) population, areas of great opioid burden, locations where the MMU can be safely parked to provide services, and locations where the MMU can be accessible by patients.

6. What level of service (number of clients) does OASAS expect for each funded project?

Response: The projected number of clients served per Mobile Medication Unit (MMU) is dependent on the service area(s) and should consider the needs justification of that Economic

Development Zone. While there are logistical and geographical differences within each Economic Development Zone, each MMU is expected to be in operation for a minimum of 3 hours per day, 6 days per week. Note that operating hours do not include any travel or prep time.

7. How many locations do you have to serve in a given service area?

Response: The number of locations/"stops" of each Mobile Medication Unit will differ depending on the needs of that specific Economic Development Zone, as well as the main patient population served by the MMU. As an example, an MMU serving only long-term care facilities, congregate care settings, or correctional facilities will have different locations and number of locations as compared to another MMU serving the public. Opioid Treatment Programs should aim to identify the locations and/or number of locations depending on the need justification for that Economic Development Zone. OASAS urges providers to determine a set schedule for where and when an MMU will be deployed to a said location.

8. What is involved in obtaining DEA approval to operate an MMU?

Response: Upon successfully obtaining NYS' approval, the Opioid Treatment Program (OTP) must notify the local DEA office, in writing, of its intent to operate a Mobile Medication Unit (MMU). The OTP must then await the receipt of explicit written approval from the DEA before beginning operations. Full details on this process can be found on the DEA's Final Rule on "Registration Requirements for Narcotic Treatment Programs with Mobile Components": <https://www.federalregister.gov/documents/2021/06/28/2021-13519/registration-requirements-for-narcotic-treatment-programs-with-mobile-components>

9. Is there a bidders conference for this funding opportunity?

Response: No.